中文摘要：
結直腸癌（CRC）對大多數免疫療法仍具有難治性，癌癥疫苗由于免疫抑制性腫瘤微環境而失敗。在這里，我們展示了β-葡聚糖誘導的訓練免疫通過H3K4me3依賴的表觀遺傳修飾和代謝重編程重塑巨噬細胞，從而克服這些障礙。在接種了肽包被腺病毒疫苗PeptiCrad的雌性小鼠中，訓練增強了糖酵解，肌酸代謝維持CXCL9/10的產生，使巨噬細胞能夠通過CXCR3招募NK細胞。反過來，NK細胞產生CCL5，推動cDC1浸潤和抗原呈遞，這共同增強了效應記憶CD8? T細胞應答。此外，在人體外周血單核細胞和CRC患者衍生的類器官中，訓練的巨噬細胞增強了NK細胞遷移、抗原特異性T細胞激活和腫瘤殺傷。這些發現凸顯了訓練免疫作為強效佐劑，以重新激活結直腸癌疫苗應答的潛力。
英文摘要：
Colorectal cancer (CRC) remains refractory to most immunotherapies, with cancer vaccines failing due to an immunosuppressive tumor microenvironment. Here, we show that β-glucan–induced trained immunity overcomes these barriers by reprogramming macrophages through H3K4me3-dependent epigenetic modifications and metabolic rewiring. In female mice vaccinated with peptide-coated adenovirus-based vaccine PeptiCrad, training enhances glycolysis with creatine metabolism sustaining CXCL9/10 production, enabling macrophages to recruit NK cells via CXCR3. In turn, NK cells produce CCL5, driving cDC1 infiltration and antigen presentation, which together amplify effector memory CD8? T cell responses. Moreover, with human peripheral blood mononuclear cells and CRC patient-derived organoids, trained macrophages boost NK migration, antigen-specific T cell activation, and tumor killing. These findings highlight trained immunity as a powerful adjuvant to reinvigorate colorectal cancer vaccination.
論文信息：
論文題目：Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response
期刊名稱：Nature Communications
時間期卷：17, Article number: 1757(2026)
在線時間：2026年1月28日
DOI： doi.org/10.1038/s41467-026-68466-5
產品信息：
貨號：C-005
規格：5ml
品牌：Liposoma
產地：荷蘭
名稱：Clodronate Liposomes氯膦酸鹽脂質體
辦事處：靶點科技
Clodronate Liposomes氯膦酸鹽脂質體清除結腸癌小鼠腫瘤模型中巨噬細胞 ，荷蘭Liposoma巨噬細胞清除劑ClodronateLiposomes見刊于Nature Communications：利用β-葡聚糖誘導的訓練免疫對巨噬細胞進行表觀遺傳和代謝重編程以增強結直腸癌疫苗反應。
Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質體清除腫瘤相關巨噬細胞的材料和方法：
For macrophage depletion, mice were administered i.p. with 200?µl of chlodronate liposomes (Liposoma, Cat# C-005) 1?day after tumor implantations and then every four days until the end of the experiment. As for NK depletion, mice were treated with 50?μl of anti-Asialo-GM1 antibodies (Purified anti-Asialo-GM1 Antibody, BioLegend, Cat # 146002) day after tumor implantations and given every four days until the end of the experiment. For depletion of both immune population, mice were treated with both treatments 1?day after tumor implanations and given every four days until the end of the experiment. For CD8?+?T cell depletion, mice were given a bolus treatment of 500?µg of anti-CD8 antibody (BioXcell, Cat# #BE0061) given I.P 1 day prior the first PC treatment and was further sustained by injecting 100?µg of anti-CD8 antibody I.P every 3 days.
材料和方法文獻截圖：
研究結論示意圖：
